Vincennes, France

Guillaume Boissy



Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2008-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Guillaume Boissy

Introduction

Guillaume Boissy, an innovative inventor based in Vincennes, France, has made significant contributions to the field of biochemistry. With a focus on therapeutic applications, Boissy has developed innovative compounds that address critical health challenges.

Latest Patents

Guillaume Boissy holds two notable patents, reflecting his commitment to advancing medical science. His latest inventions include:

1. **Cysteine protease inhibitors and their therapeutic applications** - This invention concerns new compounds of formula (I), outlining their preparation process and therapeutic uses.

2. **Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications** - This patent emphasizes the discovery of new compounds of formula (I) and elaborates on their preparation and uses in therapeutic contexts.

Career Highlights

Guillaume works with Hybrigenics S.A., a company dedicated to the research and development of innovative therapeutic solutions. Through his role there, he has been able to focus on significant advancements in protease inhibitors, highlighting his expertise in biopharmaceutical development.

Collaborations

In his professional journey, Guillaume has collaborated with esteemed colleagues, including Philippe Guedat and Catherine Borg-Capra. These collaborations have enriched his work and diversified the impact of his innovations in the biochemistry landscape.

Conclusion

Guillaume Boissy's contributions to the field of therapeutic invention illustrate the importance of innovation in healthcare. With his novel patents and collaborations, he continues to push the boundaries of science, aiming to improve health outcomes through biochemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…